Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1) → HCID 86708811, compound

HRID 1751718Notes

Reaction equation

HRID 1751718 reaction equation
[CH3:1][O:2][CH2:3][C@@H:4]1[CH2:8][NH:7][C@H:6]([C:9]2[NH:10][C:11]([C:14]3[CH:27]=[C:26]4[O:28][CH2:29][C:23]5[C:24]6[C:25]4=[C:16]([CH2:17][O:18][C:19]=6[CH:20]=[C:21]([C:30]4[NH:34][C:33]([C@@H:35]6[CH2:39][C@H:38]([CH3:40])[CH2:37][N:36]6[C:41](=[O:54])[C@H:42]([NH:49][C:50](=[O:53])[O:51][CH3:52])[C:43]6[CH:48]=[CH:47][CH:46]=[CH:45][CH:44]=6)=[N:32][CH:31]=4)[CH:22]=5)[CH:15]=3)=[CH:12][N:13]=2)[CH2:5]1.[CH3:55][O:56][C@H:57]([CH3:67])[C@H:58]([NH:62][C:63]([O:65][CH3:66])=[O:64])[C:59](O)=[O:60].CN(C(ON1N=NC2C=CC=NC1=2)=[N+](C)C)C.F[P-](F)(F)(F)(F)F>CCN(C(C)C)C(C)C.CN(C=O)C>[CH3:66][O:65][C:63]([NH:62][C@@H:58]([C@H:57]([O:56][CH3:55])[CH3:67])[C:59]([N:7]1[CH2:8][C@@H:4]([CH2:3][O:2][CH3:1])[CH2:5][C@H:6]1[C:9]1[NH:10][C:11]([C:14]2[CH:27]=[C:26]3[O:28][CH2:29][C:23]4[C:24]5[C:25]3=[C:16]([CH2:17][O:18][C:19]=5[CH:20]=[C:21]([C:30]3[NH:34][C:33]([C@@H:35]5[CH2:39][C@H:38]([CH3:40])[CH2:37][N:36]5[C:41](=[O:54])[C@H:42]([NH:49][C:50](=[O:53])[O:51][CH3:52])[C:43]5[CH:44]=[CH:45][CH:46]=[CH:47][CH:48]=5)=[N:32][CH:31]=3)[CH:22]=4)[CH:15]=2)=[CH:12][N:13]=1)=[O:60])=[O:64]

Participants

6

Reactant 3

HCID 9886157Methanaminium, N-((dimethylamino)(3H-1,2,3-triazolo(4,5-b)pyridin-3-yloxy)methylene)-N-methyl-, hexafluorophosphate(1-) (1:1)2×HCID 59540170(2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid2×HCID 86708810HCID 86708810, compound

Product 1

HCID 86708811HCID 86708811, compound

Reagents, catalysts & solvents 2

HCID 6228DimethylformamideSolventHCID 81531DiisopropylethylamineSolvent

Procedure

A mixture of methyl (R)-2-((2S,4S)-2-(5-(7-(2-((2S,4S)-4-(methoxymethyl)pyrrolidin-2-yl)-1H-imidazol-5-yl)-5,10-dihydrochromeno[5,4,3-cde]chromen-2-yl)-1H-imidazol-2-yl)-4-methylpyrrolidin-1-yl)-2-oxo-1-phenylethylcarbamate (90 mg, >0.123 mmol), (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid (26 mg, 0.135 mmol), HATU (51 mg, 0.135 mmol) in 1.5 mL 10% DIPEA in DMF was stirred for 1 hour. An additional 0.135 mmol of (2S,3R)-3-methoxy-2-(methoxycarbonylamino)butanoic acid and HATU were added and stirring continued for 3 hours. The crude product was purified by reverse phase HPLC to product (22 mg) as a trifluoroacetate salt.

Workup

  1. stirringstirring
  2. waitcontinued for 3 hours
  3. customThe crude product was purified by reverse phase HPLC to product (22 mg) as a trifluoroacetate salt

Sources & evidence

ORD record
ord-cb1eafc027fd426196958f0f80070199
Source dataset
uspto-grants-2015_10
Patent number
US09156823B2

Reaction notes

Loading…